Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis

BACKGROUND: This Bayesian network meta-analysis (NMA) was conducted to compare efficacy and safety of programmed death 1/ligand 1 (PD-1/L1) inhibitors in previous untreated advanced non-small cell lung cancer (NSCLC) patients. METHODS: Eligible studies evaluating first-line anti-PD-1/L1 based regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hengrui, Lin, Guo, Wang, Wei, Huang, Jun, Yang, Yilin, Lan, Yuting, Wang, Runchen, Cui, Fei, Hao, Zhexue, Deng, Hongsheng, Zhao, Shen, Cheng, Bo, Xiong, Shan, Li, Jianfu, Li, Caichen, Liu, Jun, He, Jianxing, Liang, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225152/
https://www.ncbi.nlm.nih.gov/pubmed/32420059
http://dx.doi.org/10.21037/tlcr.2020.02.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225152/
https://www.ncbi.nlm.nih.gov/pubmed/32420059
http://dx.doi.org/10.21037/tlcr.2020.02.14

Ejemplares similares